248 related articles for article (PubMed ID: 38167338)
21. DNA damage-triggered activation of cGAS-STING pathway induces apoptosis in human keratinocyte HaCaT cells.
Li C; Liu W; Wang F; Hayashi T; Mizuno K; Hattori S; Fujisaki H; Ikejima T
Mol Immunol; 2021 Mar; 131():180-190. PubMed ID: 33423764
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-324-5p-CUEDC2 Axis Mediates Gain-of-Function Mutant p53-Driven Cancer Stemness.
Ghatak D; Datta A; Roychowdhury T; Chattopadhyay S; Roychoudhury S
Mol Cancer Res; 2021 Oct; 19(10):1635-1650. PubMed ID: 34257080
[TBL] [Abstract][Full Text] [Related]
23. Mycoplasma infection suppresses p53, activates NF-kappaB and cooperates with oncogenic Ras in rodent fibroblast transformation.
Logunov DY; Scheblyakov DV; Zubkova OV; Shmarov MM; Rakovskaya IV; Gurova KV; Tararova ND; Burdelya LG; Naroditsky BS; Ginzburg AL; Gudkov AV
Oncogene; 2008 Jul; 27(33):4521-31. PubMed ID: 18408766
[TBL] [Abstract][Full Text] [Related]
24. The interplay between mutant p53 and the mevalonate pathway.
Parrales A; Thoenen E; Iwakuma T
Cell Death Differ; 2018 Mar; 25(3):460-470. PubMed ID: 29238070
[TBL] [Abstract][Full Text] [Related]
25. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer.
Cooks T; Pateras IS; Tarcic O; Solomon H; Schetter AJ; Wilder S; Lozano G; Pikarsky E; Forshew T; Rosenfeld N; Harpaz N; Itzkowitz S; Harris CC; Rotter V; Gorgoulis VG; Oren M
Cancer Cell; 2013 May; 23(5):634-46. PubMed ID: 23680148
[TBL] [Abstract][Full Text] [Related]
26. The cGAS/STING/TBK1/IRF3 innate immunity pathway maintains chromosomal stability through regulation of p21 levels.
Basit A; Cho MG; Kim EY; Kwon D; Kang SJ; Lee JH
Exp Mol Med; 2020 Apr; 52(4):643-657. PubMed ID: 32284536
[TBL] [Abstract][Full Text] [Related]
27. Regulators of Oncogenic Mutant TP53 Gain of Function.
Yamamoto S; Iwakuma T
Cancers (Basel); 2018 Dec; 11(1):. PubMed ID: 30577483
[TBL] [Abstract][Full Text] [Related]
28. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.
Pavlakis E; Neumann M; Merle N; Wieboldt R; Wanzel M; Ponath V; Pogge von Strandmann E; Elmshäuser S; Stiewe T
J Exp Clin Cancer Res; 2023 Aug; 42(1):203. PubMed ID: 37563605
[TBL] [Abstract][Full Text] [Related]
29. Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches.
Alvarado-Ortiz E; de la Cruz-López KG; Becerril-Rico J; Sarabia-Sánchez MA; Ortiz-Sánchez E; García-Carrancá A
Front Cell Dev Biol; 2020; 8():607670. PubMed ID: 33644030
[TBL] [Abstract][Full Text] [Related]
30. From mutational inactivation to aberrant gain-of-function: Unraveling the structural basis of mutant p53 oncogenic transition.
Olotu FA; Soliman MES
J Cell Biochem; 2018 Mar; 119(3):2646-2652. PubMed ID: 29058783
[TBL] [Abstract][Full Text] [Related]
31. TP53 gain-of-function mutation promotes inflammation in glioblastoma.
Ham SW; Jeon HY; Jin X; Kim EJ; Kim JK; Shin YJ; Lee Y; Kim SH; Lee SY; Seo S; Park MG; Kim HM; Nam DH; Kim H
Cell Death Differ; 2019 Mar; 26(3):409-425. PubMed ID: 29786075
[TBL] [Abstract][Full Text] [Related]
32. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation.
Chen X; Zhang T; Su W; Dou Z; Zhao D; Jin X; Lei H; Wang J; Xie X; Cheng B; Li Q; Zhang H; Di C
Cell Death Dis; 2022 Nov; 13(11):974. PubMed ID: 36400749
[TBL] [Abstract][Full Text] [Related]
33. Mutant p53 in Cancer Progression and Targeted Therapies.
Zhu G; Pan C; Bei JX; Li B; Liang C; Xu Y; Fu X
Front Oncol; 2020; 10():595187. PubMed ID: 33240819
[No Abstract] [Full Text] [Related]
34. Gain-of-function miRNA signature by mutant p53 associates with poor cancer outcome.
Zhang Y; Hu Y; Fang JY; Xu J
Oncotarget; 2016 Mar; 7(10):11056-66. PubMed ID: 26840456
[TBL] [Abstract][Full Text] [Related]
35. Anti-apoptotic NF-κB and "gain of function" mutp53 in concert act pro-apoptotic in response to UVB+IL-1 via enhanced TNF production.
Müller I; Beissert S; Kulms D
J Invest Dermatol; 2015 Mar; 135(3):851-860. PubMed ID: 25380350
[TBL] [Abstract][Full Text] [Related]
36. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.
Schulz-Heddergott R; Stark N; Edmunds SJ; Li J; Conradi LC; Bohnenberger H; Ceteci F; Greten FR; Dobbelstein M; Moll UM
Cancer Cell; 2018 Aug; 34(2):298-314.e7. PubMed ID: 30107178
[TBL] [Abstract][Full Text] [Related]
38. The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer.
Liu J; Zhang C; Xu D; Zhang T; Chang CY; Wang J; Liu J; Zhang L; Haffty BG; Zong WX; Hu W; Feng Z
J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36749630
[TBL] [Abstract][Full Text] [Related]
39. Triggering of the cGAS-STING Pathway in Human Plasmacytoid Dendritic Cells Inhibits TLR9-Mediated IFN Production.
Deb P; Dai J; Singh S; Kalyoussef E; Fitzgerald-Bocarsly P
J Immunol; 2020 Jul; 205(1):223-236. PubMed ID: 32471881
[TBL] [Abstract][Full Text] [Related]
40. Precise pancreatic cancer therapy through targeted degradation of mutant p53 protein by cerium oxide nanoparticles.
Zhang H; Zhang W; Hu B; Qin X; Yi T; Ye Y; Huang X; Song Y; Yang Z; Qian J; Zhang Y
J Nanobiotechnology; 2023 Apr; 21(1):117. PubMed ID: 37005668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
